Abstract
Studies in humans strongly implicate T(h)17 cells in the pathogenesis of inflammatory bowel disease. Thus, T(h)17 cells are major targets of approved and emerging biologics. Herein, we review the role of T(h)17 in IBD with a clinical focus.